Kla-TAT peptide and HPRP-A1 co-administration show synergistic effects on non-small cell lung cancer (NSCLC) A549 cells, including the promotion of mechanical disruption and apoptosis induced by a caspase-dependent pathway, and the arrest in G1 phase by the down-regulating cyclin-D1. This evidence concerns the gene KL and non-small cell lung carcinoma.